• Home
  • KBI Biopharma Inc.

KBI Biopharma Inc.

About KBI Biopharma Inc.

KBI Biopharma, a JSR Life Sciences company, is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com.

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at  www.selexis.com

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • US
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Primary activities
Biopharmaceutical
Contract Manufacturer
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
8 - 10 October 2024
View Exhibitor Profile

Products from KBI Biopharma Inc. (15)

  • Cell Line Development

    Product Cell Line Development

    KBI offers a full suite of CLD across both mammalian and microbial expression systems. KBI can apply established mammalian recombinant protein expression systems to provide rapid and industry-leading cell line generation services using: CHO-M Selexis SUREtechnology, CHO-ZN, CHO-DG44, CHO-S, and CHO-K1 GS. ...
  • Process Development

    Product Process Development

    The clinical and commercial success of biotherapeutics hinges on developing robust, reproducible, and scalable processes. KBI's extensive process development and analytical development capabilities help our partners generate active products at an attractive cost while enabling rapid, reliable transfer to c...
  • Analytical Development

    Product Analytical Development

    With top expertise in protein analytics, KBI has successfully completed over 3300 analytical projects for more than 300 customers and more than 130 distinct molecules.


    Our experience includes antibodies (IgG1, IgG4, IgM, FAb, ADC, Fc fusion), enzymes, cytokines, growth factors, highly glycosylat...
  • Formulation Development

    Product Formulation Development

    KBI’s approach to formulation development is based on the strategic pairing of two complementary scientific disciplines:
    • Establishing a comprehensive understanding of the thermal, physical, chemical, and conformational stability. • Employing statistical design-of-experiment (DOE) to evaluate main ef...
  • Characterization

    Product Characterization

    Scale-down process characterization studies performed using a qualified scale-down model are a critical part of licensure applications for biologics. 

    KBI has significant expertise in the design and execution of these studies to enable customers to define their process control strategy to take ...
  • Clinical Manufacturing

    Product Clinical Manufacturing

    KBI Biopharma offers a broad range of cGMP biologics manufacturing services to biopharmaceutical companies worldwide. Our capabilities include reliable manufacturing for preclinical and clinical supply.

    KBI’s experienced team produces high-quality therapeutics and vaccines thro...
  • cGMP Mammalian Production

    Product cGMP Mammalian Production

    KBI offers global cGMP Mammalian Production, and organizational highlights include:  • First CDMO to implement 2,000L single-use cGMP operations • High throughput single-use technology (AKTA Ready XL, 2500L SUM, 12m2 TFF) • A broad range of cGMP biologics manufacturing services from pre-clinical thr...
  • cGMP Microbial Production

    Product cGMP Microbial Production

    The KBI Boulder facility has extensive experience in generating E. coli based expression systems for high-level expression of recombinant proteins, typically using T7 expression in the BL21(DE3) strain as a platform. Following demonstration of expression in shake flasks, fermentation development ...
  • Commercial Mass Spectrometry Services

    Product Commercial Mass Spectrometry Services

    Mass spectrometry is among the most powerful analytical techniques available for protein characterization. KBI’s state-of-the-art mass spectrometry core facility delivers unparalleled structural characterization services to our clients. 
    Our expert team brings decades of experience in protein and p...
  • Cell Therapy Services

    Product Cell Therapy Services

    KBI's Cell Therapy team, located in The Woodlands, TX, has managed a fully functional manufacturing facility supporting cell therapies and developing therapies under IND since 2001. Our team has substantial expertise and knowledge in cellular therapies' manufacturing, process development, and regulato...
  • PUREplatform™

    Product PUREplatform™

    At KBI Biopharma, our PUREplatform is everything you need to make a protein. Containing plasmids, strains, media, and a fermentation process that all fit together into a service package catered to your needs. 

    • Features our PUREcoli™ cell line, our proprietary high-producing E. coli ce...
  • SUREmAb™

    Product SUREmAb™

    Built on the SUREtechnology Platform, SUREmAb optimizes monoclonal antibody (mAb) development and manufacturing processes, fast-tracking the path to clinic and market. • Fast-tracked for efficiency and speed, taking you from DNA transfection to GMP drug substance in 11 months • Comprehensive mAb develop...
show all 15 products

KBI Biopharma Inc. Resources (18)

  • CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 2

    News CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 2

    This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force? 
    15 Nov 2023
  • Navigating a New Standard in Microbial Protein Expression

    Whitepaper Navigating a New Standard in Microbial Protein Expression

    An ideal therapeutic protein “factory” creates a pure target product with high titers from the start, which can minimize development risk, timelines, and cost. E. coli has long been implemented as a therapeutic protein factory due to its simplicity, tractability, and wealth of information characterizing the microbe.

    While common E. coli expression strains alter as many as five genes to improve one aspect of recombinant protein expression, KBI has created a platform E. coli with about 1,000 genes altered and roughly 1 Mbp of DNA removed. The result is a PURE, efficient platform expression strain—PUREcoli™.

  • News Aaron Pilling Discusses the KBI PUREplatform Launch

    KBI's PUREplatform™  is a game-changing microbial expression offering that redefines biopharmaceutical manufacturing.

    Hear from Aaron Pilling, Ph.D., Senior Director of Process Development, as he discusses the KBI PUREplatform, a premium microbial CLD platform that delivers unmatched efficiencies. 
    15 Aug 2023
  • Delivering on the Promise of Bispecifics: Antibody Development

    Whitepaper Delivering on the Promise of Bispecifics: Antibody Development

    A breakthrough approach to bispecific production via streamlined workflow; cell line development to GMP manufacturing.

  • News Executive Team - About KBI & Selexis Operational Consolidation

    Hear from our parent company JSR Life Sciences and our executive team about the operational consolidation of KBI and Selexis as one organization. Get their perspective on how this brings us one step further on the path of becoming the icon of next-generation CDMOs and how the benefits translates for our partners.
    15 Aug 2023
  • Titration Curve Modeling in Bioassay Potency Method Development

    Video Titration Curve Modeling in Bioassay Potency Method Development

    In the contract laboratory environment, the time constraint is ever-present and works against both the contract lab and the client or sponsor. This is especially true for the cell-based potency testing teams, where the assays have an infinite number of variables ranging from optimal growth conditions to the generation of the ideal titration curve to accurately measure any effect on the targeted mechanism of action. To overcome this ever-present hurdle, the Cell-Based Assay Team at KBI utilizes a titration curve modeling tool to effectively predict the cellular response to an agonist or antagonist.
  • KBI Strengthens Leadership With Executive Appointments

    News KBI Strengthens Leadership With Executive Appointments

    KBI announces four recent executive appointments to continue its momentum and vision of becoming a next-generation CDMO. Joining the company are Tony Fraij, COO; Shaguna Seth, Chief of Staff and Global PMO Leader; Katie Edgar, SVP of Corporate Strategy and Alliance Management; and Sarah Wakefield, SVP, Corporate Communications.
    15 Aug 2023
  • BsAbs purification with affinity capture and mix-mode chromatography

    Webinar BsAbs purification with affinity capture and mix-mode chromatography

    Watch the webinar to see how KBI Biopharma and JSR Life Sciences have developed processes for the purification of bispecific antibodies using Amsphere™ A3 affinity chromatography followed by two polishing steps to eliminate undesirable homodimers and other impurities.
    In this webinar, we discuss bispecifics purification, including:- Challenges of bispecifics purification
    - Protein A affinity capture chromatography design
    - Comparison of Protein A resin and alternative affinity capture resin for bispecifics
    - Mixed-mode Chromatography design for bispecifics

  • News Unveiling KBI PUREplatform™, a Game-Changing Microbial Offering

    KBI announced the launch of KBI PUREplatform™, a premium microbial cell line development platform that features unmatched efficiencies for biopharmaceutical production. A culmination of decades of expertise, the platform addresses challenges, empowering customers to bring products to market cheaper and easier.
    9 Aug 2023
  • Streamlined Development and Production of Bispecific Antibodies

    Webinar Streamlined Development and Production of Bispecific Antibodies

    There is a global need for high quality, effective off-the-shelf therapies that can be used immediately, while concurrently avoiding supply chain issues and mitigating process complexities. Bispecific antibodies (bsAbs) are constructed to help meet this need due to their ability to bind to two or more different epitopes, thereby allowing them to perform multiple discrete mechanisms of action.

    This webinar will demonstrate a breakthrough platform approach that encompasses the efficient production of bispecific molecules in an integrated, streamlined way, from CLD (cell line development) to cGMP manufacturing. The leverageable integrated workflow from KBI Biopharma and Selexis generates high quality clinical bulk drug substances under accelerated timelines.

  • KBI Appoints Marykay Marchigiani CFO and Sigma Mostafa, Ph.D., CSO

    News KBI Appoints Marykay Marchigiani CFO and Sigma Mostafa, Ph.D., CSO

    Durham, North Carolina (May 10, 2023)  – KBI, a JSR Life Sciences company, today announced the appointment of Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific Officer. The additions will allow KBI to fulfill its growth strategy of becoming a next-generation CDMO.
    9 Aug 2023
  • Development of Protein A Continuous Chromatography

    Webinar Development of Protein A Continuous Chromatography

    In this Webinar, KBI Biopharma, in collaboration with JSR Life Sciences, introduces a hybrid approach to multicolumn continuous chromatography (MCC) that converts the Protein A (ProA) capture chromatography step to a continuous chromatography process, offering many of the advantages of the MCC process while avoiding the challenges associated with connecting process steps.

    Rapid advances in intensifying upstream processes for biologics production to achieve higher titers have left downstream processing as a potential bottleneck in the manufacturing scheme. MCC is an emerging technology that can significantly reduce material costs and time in plant. This mode of chromatography can lead to shorter processing times and improve efficiency as well as productivity compared to a traditional batch process.

    Here, we focus on the conversion of a batch ProA step using Amsphere A3 resin to a 4-column continuous process on a BioSMB system.
  • KBI Appoints David Stewart Site Head of Durham cGMP Facility

    News KBI Appoints David Stewart Site Head of Durham cGMP Facility

    Stewart has more than two decades of biotech leadership experience and a proven record of delivering best-in-class supply for patients. He will oversee all operations at Patriot Park, Durham, North Carolina, driving deliverables for KBI’s global biopharmaceutical customers.

    9 Aug 2023
  • KBI Geneva Inaugural FIH Batch Released Five Months After Opening

    News KBI Geneva Inaugural FIH Batch Released Five Months After Opening

    In late 2022, KBI successfully released its inaugural FIH manufacturing batch in compliance with cGMP standards in its recently expanded Geneva mammalian cell manufacturing facility. This important milestone demonstrates the capabilities of KBI, allowing clients to accelerate clinical research timelines.
    8 Aug 2023
  • KBI Biopharma Announced as 2023 ISPE Facility Finalist

    News KBI Biopharma Announced as 2023 ISPE Facility Finalist

    KBI Biopharma is thrilled to announce that its Patriot Park facility has been named a finalist in the 2023 ISPE Facility Of The Year Aawards (FOYA) in two categories: operations and pharma 4.0
    8 Aug 2023
  • Subcontract with Mapp on Sudan ebolavirus Treatment

    News Subcontract with Mapp on Sudan ebolavirus Treatment

    Following the recent Sudan ebolavirus outbreak in Uganda, KBI is providing emergency support through global production efforts.KBI announced it entered into a subcontract with Mapp for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus.
    8 Aug 2023
  • KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO

    News KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO

    KBI Biopharma and Selexis, announced in April 2023 the appointment of J.D. Mowery as CEO. Widely respected as an innovative biotech leader with a nearly 25-year track record of successfully inspiring colleagues and building organizations, J.D. will lead KBI and Selexis into becoming a leader in the next CDMO generation.
    8 Aug 2023
  • Streamlined Development for Efficient Production of Bispecific Molecules: Connect to Frankfurt on-demand

    News Streamlined Development for Efficient Production of Bispecific Molecules: Connect to Frankfurt on-demand

    In this Connect to Frankfurt session, Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overview of a streamlined process for the production of bispecific molecules.  
    7 Oct 2022